Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Koji Haratani"'
Autor:
Ryohei Yoshida, Maria Saigi, Tetsuo Tani, Benjamin F. Springer, Hirofumi Shibata, Shunsuke Kitajima, Navin R. Mahadevan, Marco Campisi, William Kim, Yoshihisa Kobayashi, Tran C. Thai, Koji Haratani, Yurie Yamamoto, Shriram K. Sundararaman, Erik H. Knelson, Amir Vajdi, Israel Canadas, Ravindra Uppaluri, Cloud P. Paweletz, Juan J. Miret, Patrick H. Lizotte, Prafulla C. Gokhale, Pasi A. Jänne, David A. Barbie
Publikováno v:
Cancer Res
Immunotherapy has shown limited efficacy in patients with EGFR-mutated lung cancer. Efforts to enhance the immunogenicity of EGFR-mutated lung cancer have been unsuccessful to date. Here, we discover that MET amplification, the most common mechanism
Autor:
Kimio Yonesaka, Junko Tanizaki, Osamu Maenishi, Koji Haratani, Hisato Kawakami, Kaoru Tanaka, Hidetoshi Hayashi, Kazuko Sakai, Yasutaka Chiba, Asuka Tsuya, Hiroki Goto, Eri Otsuka, Hiroaki Okida, Maki Kobayashi, Ryoto Yoshimoto, Masanori Funabashi, Yuuri Hashimoto, Kenji Hirotani, Takashi Kagari, Kazuto Nishio, Kazuhiko Nakagawa
Publikováno v:
Clinical Cancer Research. 28:390-403
Purpose: EGFR-tyrosine kinase inhibitor (TKI) is a standard first-line therapy for activated EGFR-mutated non–small cell lung cancer (NSCLC). Treatment options for patients with acquired EGFR-TKI resistance are limited. HER3 mediates EGFR-TKI resis
Autor:
Shinichiro, Suzuki, Kimio, Yonesaka, Takeshi, Teramura, Toshiyuki, Takehara, Ryoji, Kato, Hitomi, Sakai, Koji, Haratani, Junko, Tanizaki, Hisato, Kawakami, Hidetoshi, Hayashi, Kazuko, Sakai, Kazuto, Nishio, Kazuhiko, Nakagawa
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(20)
Treatment withClones of sotorasib-sensitiveUnbiased screening detected subclonal evolution of
Autor:
Kimio Yonesaka, Kazuhiko Nakagawa, Koji Haratani, Yoshikane Nonagase, Masayuki Takeda, Tomoaki Hoshino, Hidenobu Ishii, Koichi Azuma, Kaoru Tanaka, Hidetoshi Hayashi
Publikováno v:
Thoracic Cancer, Vol 10, Iss 10, Pp 1928-1935 (2019)
Thoracic Cancer
Thoracic Cancer
Background Non-small cell lung cancer (NSCLC) positive for activating mutations of the epidermal growth factor receptor (EGFR) gene is initially sensitive to EGFR-tyrosine kinase inhibitors (TKIs) but eventually develops resistance to these drugs. Up
Autor:
Naoki Takegawa, Hidetoshi Hayashi, Hisato Kawakami, Junji Tsurutani, Junko Tanizaki, Kazuhiko Nakagawa, Kimio Yonesaka, Satomi Watanabe, Masayuki Takeda, Koji Haratani, Yoshikane Nonagase
Publikováno v:
Cancer Medicine
HER2‐targeted therapy, especially the anti‐HER2 antibody trastuzumab, is standard for HER2‐positive breast cancer; however, its efficacy is limited in a subpopulation of patients. HER3 ligand (heregulin)‐dependent HER2‐HER3 interactions pla
Autor:
Koji Haratani, Yasutaka Chiba, Shiki Takamura, Takafumi Okabe, Kenji Hirotani, Hiroyasu Kaneda, Michiko Yamato, Kaoru Tanaka, Shigeki Kato, Kazuhiko Nakagawa, Kazuto Nishio, Hidetoshi Hayashi, Yoshikazu Hasegawa, Masayuki Takeda, Kazuko Sakai, Kimio Yonesaka, Masaaki Miyazawa, Osamu Maenishi, Ryoji Kato, Naoki Takegawa, Takayuki Takahama, Hitomi Sakai, Keita Kudo
Publikováno v:
Clinical Cancer Research. 24:2653-2664
Purpose: Anti-programmed-death-1 (PD-1) immunotherapy improves survival in non–small cell lung cancer (NSCLC), but some cases are refractory to treatment, thereby requiring alternative strategies. B7-H3, an immune-checkpoint molecule, is expressed
Autor:
Kenji Hirotani, Kazuko Sakai, Satomi Watanabe, Hisato Kawakami, Takashi Kagari, Naoyuki Maeda, Kazuhiko Nakagawa, Koji Haratani, Naoki Takegawa, Kimio Yonesaka, Yasutaka Chiba, Kazuto Nishio
Publikováno v:
Oncogene. 38(9)
EGFR tyrosine kinase inhibitors (TKIs) are standard therapy for EGFR-mutant non-small cell lung cancer (NSCLC); however, these tumours eventually acquire chemoresistance. U3-1402 is an anti-HER3 antibody-drug conjugate with a novel topoisomerase I in
Autor:
Yosuke Togashi, K. Tanimura, Kazuhiko Nakagawa, Kaoru Tanaka, Hidetoshi Hayashi, Kazuko Sakai, Ken-ichiro Hayashi, Kimio Yonesaka, Takayuki Takahama, Masayuki Takeda, Hiroyasu Kaneda, Takeshi Yoshida, Koji Haratani, Yoshikane Nonagase, Tetsuya Mitsudomi, Tae Tanaka, Tadashi Ishida, Hiroshige Yoshioka, Junko Tanizaki, Shuta Tomida, Kazuto Nishio, Yasutaka Chiba
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 28(7)
The efficacy of programmed death-1 blockade in epidermal growth factor receptor gene (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) patients with different mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) is un
Autor:
Masayuki Takeda, Junko Tanizaki, Hidetoshi Hayashi, Naoki Takegawa, Koji Haratani, Yoshikane Nonagase, Takeshi Yoshida, Satomi Watanabe, Takayuki Takahama, Kimio Yonesaka, Hiroto Ueda, Takao Tamura, Junji Tsurutani, Hisato Kawakami, Kazuhiko Nakagawa, Yasutaka Chiba
Publikováno v:
Oncotarget
// Yoshikane Nonagase 1 , Kimio Yonesaka 1 , Hisato Kawakami 1 , Satomi Watanabe 1 , Koji Haratani 1 , Takayuki Takahama 1 , Naoki Takegawa 1 , Hiroto Ueda 1 , Junko Tanizaki 1 , Hidetoshi Hayashi 1 , Takeshi Yoshida 1 , Masayuki Takeda 1 , Yasutaka